Hologic

In late November 2013, activist investor Carl Icahn disclosed a 12.5% stake in the company. Subsequently, the company adopted a poison pill to prevent a hostile takeover. In negotiations with the company's board of directors, two additional directors backed by Icahn were added to the board, each managing directors of Icahn holding companies.{{cite news |title=Hologic names new CEO, adds two Icahn nominees to board |newspaper=Reuters.com |date=December 9, 2013 |last=Grover |first=Natalie |url=https://www.reuters.com/article/2013/12/09/us-hologic-icahn-idUSBRE9B80O620131209/ |url-status=live |archive-url=https://web.archive.org/web/20181001220533/https://www.reuters.com/article/us-hologic-icahn/hologic-names-new-ceo-adds-two-icahn-nominees-to-board-idUSBRE9B80O620131209 |archive-date=October 1, 2018}} Icahn considered his investment and intervention into Hologic to have been a success, with his nominees to the board of directors resigning on March 3, 2016{{cite web |title=Carl Icahn cashes in on Hologic success |date=March 4, 2016 |last=Adams |first=Dan |website=Boston Globe |url=https://www.bostonglobe.com/business/2016/03/04/carl-icahn-cashes-hologic-success/vry84HeJrU9HEmIvc0BceO/story.html |access-date=January 6, 2020 |url-status=live |archive-url=https://web.archive.org/web/20190903042516/https://www.bostonglobe.com/business/2016/03/04/carl-icahn-cashes-hologic-success/vry84HeJrU9HEmIvc0BceO/story.html |archive-date=September 3, 2019}} and exiting his position by May 16, 2016.{{cite web |title=Icahn exits Gannett, Hologic positions; adds to Xerox |last=Witkowski |first=Wallace |date=May 6, 2016 |website=MarketWatch.com |url=https://www.marketwatch.com/story/icahn-exits-gannett-hologic-positions-adds-to-herbalife-xerox-2016-05-16 |access-date=January 6, 2020 |url-status=live |archive-url=https://web.archive.org/web/20170705051047/https://www.marketwatch.com/story/icahn-exits-gannett-hologic-positions-adds-to-herbalife-xerox-2016-05-16 |archive-date=July 5, 2017}}

In 2017, Hologic acquired Westford, Massachusetts-based aesthetic medicine company Cynosure for $1.65 billion.{{cite web |title=Breast imaging company Hologic unloads aesthetics line at $1B-plus loss |last=Stempniak |first=Marty |date=January 3, 2020 |website=RadiologyBusiness.com |url=https://radiologybusiness.com/topics/healthcare-management/healthcare-economics/breast-imaging-hologic-aesthetics-line-cynosure |access-date=January 15, 2025 |url-status=live |archive-url=https://web.archive.org/web/20200106070204/https://www.radiologybusiness.com/topics/healthcare-economics/breast-imaging-hologic-aesthetics-line-cynosure |archive-date=January 6, 2020}}

On November 20, 2019, Hologic announced the divestment of Cynosure to Clayton, Dubilier & Rice for $205 million;{{Cite web |last=Rosen |first=Andy |date=November 20, 2019 |title=Hologic just sold a company for less than a tenth of the $1.6b it paid two years ago |url=https://www.bostonglobe.com/business/2019/11/20/hologic-just-sold-company-for-less-than-tenth-paid-two-years-ago/GkjvXTKquv7ap9jw7MBe1K/story.html |access-date=April 30, 2025 |website=The Boston Globe}} this was completed on December 30, 2019.{{Citation needed|date=April 2025}} Cynosure had ~825 employees at the time of the divestiture.{{cite web |title=Hologic (HOLX) Divests Cynosure to Focus on Women's Health |date=January 2, 2020 |website=Zacks.com |url=https://www.zacks.com/stock/news/698933/hologic-holx-divests-cynosure-to-focus-on-womens-health |access-date=January 5, 2020 |url-status=live |archive-url=https://web.archive.org/web/20200106060436/https://www.zacks.com/stock/news/698933/hologic-holx-divests-cynosure-to-focus-on-womens-health |archive-date=January 6, 2020}}

In March 2020, Hologic received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic.{{cite web |title=FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits |date=19 March 2020 |website=IBTimes.com |url=https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |url-status=live |archive-url=https://web.archive.org/web/20200320210743/https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |archive-date=20 March 2020}} In May 2020, Hologic received a second emergency use authorization from the FDA for 2019-nCov to increase potential throughput of testing.{{cite web |title=Hologic's latest COVID-19 test gets FDA approval for emergency use |date=29 May 2020 |website=reuters.com |url=https://www.reuters.com/article/us-health-coronavirus-test-hologic/hologics-latest-covid-19-test-gets-fda-approval-for-emergency-use-idUSKBN22R20T/}}

In June 2020, Hologic collaborated with Grifols, a global producer of plasma-driven medicines, to increase Spain's testing capacity for COVID-19.{{cite web |title=Hologic: Grifols and Hologic embark on a unique collaboration for COVID-19 testing in Spain |date=12 June 2020 |language=en |website=MarketScreener |url=https://www.marketscreener.com/quote/stock/HOLOGIC-INC-9566/news/Hologic-Grifols-and-Hologic-embark-on-a-unique-collaboration-for-COVID-19-testing-in-Spain-30761632/ |access-date=2025-01-15}}

In November 2020, Hologic won a $119 million contract from the U.S. Department of Health and Human Services and the Department of Defense to help expand production facilities in three states, Wisconsin, Maine, and California, with the goal to provide 13 million COVID tests per month by January 2022.{{cite web |title=Hologic nets $119M U.S. government contract to boost coronavirus test manufacturing into 2022 |language=en |website=FierceBiotech |url=https://www.fiercebiotech.com/medtech/hologic-nets-119m-u-s-government-contract-to-boost-coronavirus-test-manufacturing-into-2022 |access-date=2020-11-04}}{{cite web |title=Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity |language=en |website=BaytownSun.com |url=https://baytownsun.com/coronavirus/article_7311afd3-f962-527b-bd88-aa7612e45ef5.html |access-date=2020-11-04}}

In January 2021, the company announced it would acquire Biotheranostics and its breast and metastatic cancer test portfolio for $230 million{{cite web |title=Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 million |date=5 January 2021 |url=https://www.biospace.com/article/releases/hologic-to-acquire-biotheranostics-leader-in-molecular-tests-for-breast-and-metastatic-cancers-for-approximately-230-million/?s=79}} and SOMATEX for $64 Million.{{cite web |title=Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies, for $64 Million |date=4 January 2021 |url=https://www.biospace.com/hologic-to-acquire-somatex-leader-in-biopsy-site-markers-and-localization-technologies-for-64-million}}

In April 2021, the company announced it will acquire Mobidiag, a molecular diagnostics firm with multiplex technology, for $795 million.{{cite web |last=Vinluan |first=Frank |title=Hologic makes a multiplex molecular testing move with $795M Mobidiag acquisition |date=2021-04-08 |language=en-US |website=MedCity News |url=https://medcitynews.com/2021/04/hologic-makes-a-multiplex-molecular-testing-move-with-795m-mobidiag-acquisition/ |access-date=2021-04-26}} The acquisition completed in June 2021.{{cite press release |title=Hologic Completes Acquisition of Mobidiag |publisher=Hologic |via=Business Wire |date=June 17, 2021 |url=https://www.businesswire.com/news/home/20210617005517/en/Hologic-Completes-Acquisition-of-Mobidiag}}

In March 2022, Hologic became the title sponsor of the WTA Tour in women's professional tennis. As part of the sponsorship, the company was also named the "official health partner" of the Women's Tennis Association.{{cite web |last=Clarey |first=Christopher |title=Strong Stance on China and Peng Shuai Helps Land WTA a New Title Sponsor |date=2022-03-03 |website=The New York Times |url=https://www.nytimes.com/2022/03/03/sports/tennis/wta-hologic-china.html |access-date=2022-03-03}}

In April 2024, Hologic agreed to acquire British medical device manufacturer Endomag for $310 million.{{cite news |last=Kanner-Mascolo |first=Mica |title=Hologic to acquire UK-based breast cancer tech manufacturer for $310M |date=April 30, 2024 |work=Worcester Business Journal |url=https://www.wbjournal.com/article/hologic-to-acquire-uk-based-breast-cancer-tech-manufacturer-for-310m}} The acquisition completed in July that year.{{cite web |title=Hologic completes Endomagnetics acquisition |date=July 25, 2024 |work=Mass Device |last=Kirsh |first=Danielle |url=https://www.massdevice.com/hologic-completes-endomagnetics-acquisition/}}

In 2025, Hologic acquired Gynesonics for $350 million, which developed the Sonata System, an ultrasound imaging device for uterine fibroids.{{Cite web |date=2025-01-07 |title=Hologic finalizes $350M acquisition of ultrasound imaging device developer |url=https://radiologybusiness.com/topics/healthcare-management/mergers-and-acquisitions/hologic-finalizes-350m-acquisition-ultrasound-imaging-device-developer |access-date=2025-04-30 |website=radiologybusiness.com |language=en}}

{{Reflist}}

• {{Official website}}

{{Finance links |name=Hologic |bloomberg=HOLX:US |google=HOLX |sec_cik=HOLX |yahoo=HOLX}}

{{Portal|Companies}}

{{Authority control}}

Category:American companies established in 1985

Category:Companies based in Middlesex County, Massachusetts

Category:Companies listed on the Nasdaq

Category:Health care companies based in Massachusetts

Category:Health care companies established in 1985

Category:Marlborough, Massachusetts

Category:Medical technology companies of the United States